Robert Azelby is Director of ADC Therapeutics SA. Currently has a direct ownership of 53,005 shares of ADCT, which is worth approximately $156,364. The most recent transaction as insider was on Jun 17, 2024, when has been sold 6,995 shares (Common Shares) at a price of $2.89 per share, resulting in proceeds of $20,215. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 53K
0% 3M change
n/a 12M change
Total Value Held $156,364

Robert Azelby Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 17 2024
SELL
Open market or private sale
$20,215 $2.89 p/Share
6,995 Reduced 11.66%
53,005 Common Shares
Jun 13 2024
BUY
Grant, award, or other acquisition
-
40,000 Added 40.0%
60,000 Common Shares

Also insider at

CAH
CARDINAL HEALTH INC Healthcare
KDNY
CHINOOK THERAPEUTICS, INC. Healthcare
CLVS
Clovis Oncology, Inc. Healthcare
ELYM
Eliem Therapeutics, Inc. Healthcare
IMMU
IMMUNOMEDICS INC
RA

Robert Azelby

Director
Morris Plains, NJ

Track Institutional and Insider Activities on ADCT

Follow ADC Therapeutics SA and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ADCT shares.

Notify only if

Insider Trading

Get notified when an Adc Therapeutics Sa insider buys or sells ADCT shares.

Notify only if

News

Receive news related to ADC Therapeutics SA

Track Activities on ADCT